Cantor Fitzgerald Starts Biogen (BIIB) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall St set to fall at open as yields and oil rebound; Fed minutes in focus
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $225.66 +1.24%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 18
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 18
Join SI Premium – FREE
Cantor Fitzgerald initiated coverage on Biogen (NASDAQ: BIIB) with a Neutral rating.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $286.25 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cantor Fitzgerald Upgrades Humana (HUM) to Overweight, 'A Strong 2027 Margin Year Bridges to an Inexpensive 2028 Multiple'
- Lake Street Starts Fossil (FOSL) at Buy
- Oppenheimer Starts SailPoint (SAIL) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Cantor FitzgeraldSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
